- Home
- FTV vs ILMN Comparison
FTV vs ILMN Comparison
Compare FTV & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTV
- ILMN
- Stock Information
- Founded
- FTV 2015
- ILMN 1998
- Country
- FTV United States
- ILMN United States
- Employees
- FTV N/A
- ILMN N/A
- Industry
- FTV Industrial Machinery/Components
- ILMN Medical Specialities
- Sector
- FTV Industrials
- ILMN Health Care
- Exchange
- FTV Nasdaq
- ILMN Nasdaq
- Market Cap
- FTV 26.7B
- ILMN 23.6B
- IPO Year
- FTV N/A
- ILMN 2000
- Fundamental
- Price
- FTV $73.71
- ILMN $134.03
- Analyst Decision
- FTV Buy
- ILMN Buy
- Analyst Count
- FTV 14
- ILMN 19
- Target Price
- FTV $86.73
- ILMN $162.67
- AVG Volume (30 Days)
- FTV 2.4M
- ILMN 1.8M
- Earning Date
- FTV 01-29-2025
- ILMN 02-06-2025
- Dividend Yield
- FTV 0.43%
- ILMN N/A
- EPS Growth
- FTV 7.50
- ILMN N/A
- EPS
- FTV 2.50
- ILMN N/A
- Revenue
- FTV $6,195,200,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- FTV $4.13
- ILMN N/A
- Revenue Next Year
- FTV $4.43
- ILMN $4.28
- P/E Ratio
- FTV $29.46
- ILMN N/A
- Revenue Growth
- FTV 3.06
- ILMN N/A
- 52 Week Low
- FTV $66.15
- ILMN $97.36
- 52 Week High
- FTV $87.10
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- FTV 31.65
- ILMN 37.76
- Support Level
- FTV $76.06
- ILMN $140.29
- Resistance Level
- FTV $77.34
- ILMN $148.51
- Average True Range (ATR)
- FTV 1.22
- ILMN 5.52
- MACD
- FTV -0.57
- ILMN -0.58
- Stochastic Oscillator
- FTV 1.30
- ILMN 4.47
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.1 billion in revenue in 2023.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.